Iterum Therapeutics plc (ITRMF) Non Operating Income (2017 - 2025)

Iterum Therapeutics has reported Non Operating Income for 9 years, with the latest figure at -$1.1 million in Q3 2025.

• On a quarterly basis, Non Operating Income fell 4.2% year-over-year to -$1.1 million in Q3 2025; TTM through Sep 2025 was -$6.0 million, a 61.63% decrease from a year earlier, with the FY2024 full-year figure at -$5.8 million, down 160.12% from the prior year.
• Non Operating Income was -$1.1 million for Q3 2025 at Iterum Therapeutics, down from -$921000.0 in the prior quarter.
• The five-year high for Non Operating Income was $14.9 million in Q2 2021, with the low at -$93.0 million in Q1 2021.
• Average Non Operating Income over 5 years is -$4.2 million, with a median of -$921000.0 recorded in 2025.
• The largest YoY upside for Non Operating Income was 464.47% in 2021 against a maximum downside of 2915.04% in 2021.
• Over 5 years, Non Operating Income stood at $2.8 million in 2021, then climbed by 4.22% to $2.9 million in 2022, then sank by 126.86% to -$789000.0 in 2023, then tumbled by 265.91% to -$2.9 million in 2024, then jumped by 61.34% to -$1.1 million in 2025.
• The last three Non Operating Income figures came in at -$1.1 million (Q3 2025), -$921000.0 (Q2 2025), and -$1.1 million (Q1 2025), per Business Quant data.